[
  {
    "ts": null,
    "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
    "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
    "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756315645,
      "headline": "Pfizer: Finally Some Fortune, Plus Twenty High-Quality Dividend Growth Valuations",
      "id": 136542130,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203006359/image_2203006359.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Discover high-quality dividend-growth stocks near 52-week lows. Explore Pfizer's strong dividend and valuations, plus other top picks like Merck and Qualcomm.",
      "url": "https://finnhub.io/api/news?id=ec425284e980cf083d7d06feec4294590bc48a5d33b2fdd798c828b58de26570"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=5ce200bc894dd4fd239a88ed9a6058cea834d30a451c0b11fa8ad188137c857b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756312440,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136559812,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=5ce200bc894dd4fd239a88ed9a6058cea834d30a451c0b11fa8ad188137c857b"
    }
  },
  {
    "ts": null,
    "headline": "Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics",
    "summary": "LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered ...",
    "url": "https://finnhub.io/api/news?id=277eef0b1271221f01143c765ef5e97db3e87248c0485139023b0f0823dff71d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756302300,
      "headline": "Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics",
      "id": 136536615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered ...",
      "url": "https://finnhub.io/api/news?id=277eef0b1271221f01143c765ef5e97db3e87248c0485139023b0f0823dff71d"
    }
  },
  {
    "ts": null,
    "headline": "HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy",
    "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., August 27, 2025--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer",
    "url": "https://finnhub.io/api/news?id=38666b94fa78e2085e82aff5e3e644a55e2733fdab93c927d066744e6e68c2f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756292400,
      "headline": "HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy",
      "id": 136536475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BASKING RIDGE, N.J. & RAHWAY, N.J., August 27, 2025--HERTHENA-Breast04 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic HR+/HER2- Breast Cancer",
      "url": "https://finnhub.io/api/news?id=38666b94fa78e2085e82aff5e3e644a55e2733fdab93c927d066744e6e68c2f9"
    }
  },
  {
    "ts": null,
    "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
    "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
    "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756284600,
      "headline": "Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma",
      "id": 136536324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global chronic inducible urticaria (CIndU) market is experiencing significant transformation due to rising prevalence, advancements in diagnostics, and targeted immunotherapies. Affecting 0.1% to 3% of the population, CIndU is linked to conditions like allergies and autoimmune diseases. Market growth is propelled by insights into immune mechanisms and increasing awareness among healthcare providers. Emerging diagnostic tools and biologic therapies, such as monoclonal antibodies, enhance trea",
      "url": "https://finnhub.io/api/news?id=9d461e0b4d97e55d511f3c6e3d7bd785423f7c2d101af7c9409b9c8f2264c2be"
    }
  }
]